NASDAQ · Biotechnology · USD
Curanex Pharmaceuticals Inc (CURX) Stock Analysis
Curanex Pharmaceuticals Inc (CURX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CURX Key Statistics
As of Oct 21, 2026Trading
- Open
- $4.75
- Previous Close
- $4.77
- Day's Range
- 4.69–5.01
- 52-Week Range
- 3.58–16.94
- Volume
- 5.02K
Valuation
- Market Cap
- $7.86M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −7.80
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$4.23M
- Shares Outstanding
- 1.57M
- 1-Year Return
- −57.11%
Dividend and dates
- Avg Volume
- 20.66K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CURX closed at $5.01, −57.11% over 1 year.
Curanex Pharmaceuticals Inc (CURX) has a market capitalization of $7.86M.
In fiscal 2025, CURX reported revenue of $0.00.
CURX Stock Return by Calendar Year
Curanex Pharmaceuticals Inc (CURX) return since Aug 2025: what $10,000 became
- 1 year
- $10,000 $4,289
- −57.11%
- Since Aug 2025
- $10,000 $623
- −93.77%
If you had invested $10,000 in Curanex Pharmaceuticals Inc (CURX) at the close on August 26, 2025, the earliest close on record here, it would have been worth $623 at the close on October 21, 2026: −93.77% in total, −91.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −24.32% |
| 2025 (partial year) | −91.77% |
As of October 21, 2026.
CURX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$4.23M | — |
| 2024 | $0.00 | −$361.51K | — |
| 2023 | $0.00 | −$19.20K | — |
| 2022 | $26.00K | −$20.23K | −77.8% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$4.24M | −$4.23M | — |
| 2024 | $0.00 | — | −$290.39K | −$361.51K | — |
| 2023 | $0.00 | $0.00 | −$19.30K | −$19.20K | — |
| 2022 | $26.00K | $4.43K | −$20.23K | −$20.23K | −77.8% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B